Efficacy and Safety of Coenzyme Q10 Supplementation in Neonates, Infants and Children: An Overview

David Mantle,Iain Parry Hargreaves
DOI: https://doi.org/10.3390/antiox13050530
IF: 7.675
2024-04-27
Antioxidants
Abstract:To date, there have been no review articles specifically relating to the general efficacy and safety of coenzyme Q10 (CoQ10) supplementation in younger subjects. In this article, we therefore reviewed the efficacy and safety of CoQ10 supplementation in neonates (less than 1 month of age), infants (up to 1 year of age) and children (up to 12 years of age). As there is no rationale for the supplementation of CoQ10 in normal younger subjects (as there is in otherwise healthy older subjects), all of the articles in the medical literature reviewed in the present article therefore refer to the supplementation of CoQ10 in younger subjects with a variety of clinical disorders; these include primary CoQ10 deficiency, acyl CoA dehydrogenase deficiency, Duchenne muscular dystrophy, migraine, Down syndrome, ADHD, idiopathic cardiomyopathy and Friedreich's ataxia.
biochemistry & molecular biology,chemistry, medicinal,food science & technology
What problem does this paper attempt to address?